The M&A Pool Set to Accelerate Biotech Innovation
Pathfinders in Biopharma - Een podcast door RBC Capital Markets
Categorieën:
Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.
